PHAXIAM’s Audit Committee assists our board of directors in its oversight of our corporate accounting and financial reporting and submits the selection of our statutory auditors, their remuneration and independence for approval. It is composed of Hilde Windels, Philippe Archinard and Eric Leire for the Board of Directors and Eric Soyer and Thibaut du Fayet who represent PHAXIAM’s management team.
Investors
Welcome to the PHAXIAM Therapeutics investor area
Corporate profile
PHAXIAM is a clinical-stage biopharmaceutical company developing innovative bacteriophage-based therapies to fight antimicrobial resistance (AMR).
INNOVATIVE APPROACH
PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, responsible for more than two-thirds of hospital-acquired resistant infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
PHAGES PORTFOLIO
PHAXIAM développe un portefeuille de phages ciblant 3 des bactéries les plus résistantes et les plus dangereuses, qui représentent à elles seules plus des deux tiers des infections nosocomiales résistantes : Staphylococcus aureus, Escherichia coli et Pseudomonas aeruginosa .
DUAL LISTING
PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
STOCK QUOTE
Latest press releases
Upcoming events
November 28, 2023
Investir Day - Paris - Carrousel du Louvre - https://www.investirday.fr/
December 05, 2023
Geneva MidCap Event - Royal Hotel - Participants: Thibaut du Fayet, Eric Soyer https://geneva2023.cfbcom.com/
Audit Committee
Clinical Strategy Committee
Our clinical strategy committee is responsible for analyzing and reviewing our clinical and regulatory strategy. It meets, at least once a year, and makes recommendations to PHAXIAM’s Board of Directors regarding our clinical and regulatory development strategy.
PHAXIAM’s clinical strategy committee is composed of Martine George, Philippe Archinard and Robert Sebbag for the Board of Directors and Pascal Birman, Frédérique Vieville and Thibaut du Fayet who represent PHAXIAM’s management team.
Remuneration and appointments committee+
The Remuneration and Appointments Committee hears the directors’ assessments of PHAXIAM’s performance against defined objectives. It meets at least once a year, without the directors being present, to assess their individual performance and, after conferring with them, makes recommendations to the Board of Directors concerning their remuneration.
It is composed of Philippe Archinard, Leïla Nicolas et Hilde Windels for the Board of Directors, and Eric Soyer, Chief Financiel Officer, Chief Operating Officer and Deputy General Manager of PHAXIAM.
Press releases
+++
DATE
TITLE
PDF
07/01/2025
title vvo
.png)
Past press releases
2023
Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
06/28/2023 - 22:05
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics
06/26/2023 - 22:00
Pherecydes Pharma and Erytech Pharma shareholders approve the merger between the two companies
06/23/2023 - 20:45
Commercial Court rejects Akkadian's request to postpone the merger vote: Pherecydes and Erytech shareholders will be able to vote on the merger on June 23, 2023
06/14/2023 - 20:00
Pherecydes Pharma Has Submitted An Application For The Approval Of A Phase I Clinical Study In Infective Endocarditis Caused By Staphylococcus Aureus
06/08/2023 - 07:30
Pherecydes announces that legal proceedings have been initiated against Erytech by Akkadian to obtain the postponement of the vote on the merger with Pherecydes
06/05/2023 - 08:00
Availability of the Exemption document
05/23/2023 - 22:53
PHERECYDES Strengthens its Corporate Links with ERYTECH to Prepare the Strategic Combination
05/16/2023 - 07:00
Pherecydes Pharma presented its Phagogram 1.5 at the ECCMID Congress
04/17/2023 - 07:00
TP ICAP Midcap initiates coverage of Pherecydes Pharma with a “Buy” recommendation
04/06/2023 - 17:45
Pherecydes Pharma selected for the French Tech Health20 program’s 2023 class
03/27/2023 - 07:00
Pherecydes Pharma announces its participation in several scientific and investor conferences
01/25/2023 - 17:45
Pherecydes Pharma Announces its Financial Agenda for 2023
01/03/2023 - 17:45
2022
Pherecydes Pharma: minutes of the Combined General Meeting of December 15, 2022
12/15/2022 - 18:00
Pherecydes Pharma announces the positive recommendation of the DSMB for the continuation of its phase II clinical study PhagoDAIR in osteoarticular infections caused by Staphylococcus aureus
11/29/2022 - 18:00
Pherecydes Pharma will present its phagogram’s latest progress during an oral session at the Phage Futures US 2022 conference
11/16/2022 - 07:00
Half-year 2022 financial results and update on the development plan
10/27/2022 - 17:45
Pherecydes Pharma announces its participation in a number of major scientific and investor conferences
09/27/2022 - 18:00
Pherecydes Pharma successfully completes €3.1 million capital increase
09/22/2022 - 08:30
Pherecydes Pharma launches a capital increase for c. €3m to continue its clinical development program in phage therapy
09/21/2022 - 17:35
Pherecydes Pharma announces the creation of an international Medical Advisory Board
09/15/2022 - 17:45
Pherecydes Pharma announces a first registration of its phagogram as an in vitro diagnostic test in accordance with EC Directives
09/12/2022 - 17:45
Positive preclinical results for inhaled phage therapy presented to the Reanimation 2022 conference
06/27/2022 - 07:00
Pherecydes Pharma announces the enrollment of the first patient in the phase II study PhagoDAIR in the treatment of osteoarticular infections caused by Staphylococcus aureus
06/15/2022 - 18:00
Pherecydes Pharma organizes a scientific symposium during the 23rd National Days of Infectiology
06/08/2022 - 18:00
Pherecydes Pharma obtains AAC Early Access Program approval from the ANSM for its anti-Staphylococcus aureus phages
05/30/2022 - 18:00
The general assembly of Pherecydes Pharma approves the evolution of its governance towards a company with a Board of Directors
05/23/2022 - 19:00
Pherecydes Pharma announces the first international approval of a compassionate treatment with its phages
04/28/2022 - 18:00
Pherecydes Pharma announces its 2021 annual financial results and confirms its 2022 outlook
04/14/2022 - 07:00
Pherecydes Pharma announces the appointment of Thibaut du Fayet as Chief Operating Officer and member of the Executive Board
04/07/2022 - 18:00
Pherecydes Pharma announces partnership with Navarrabiomed to evaluate its anti-S. aureus phages in a new indication
03/31/2022 - 07:00
Pherecydes Pharma granted a new patent for its anti-Pseudomonas aeruginosa phages in Europe
03/22/2022 - 07:00
Pherecydes Pharma and BIOASTER join forces in the treatment of bacteremia
03/11/2022 - 07:00
Pherecydes Pharma extends its intellectual property in China with a first patent granted for its anti-Pseudomonas aeruginosa phages in this territory
03/08/2022 - 17:45
Pherecydes Pharma announces a change in its governance structure to become a Company with a Board of Directors
02/24/2022 - 07:00
Pherecydes Pharma receives a favorable opinion from the Ethics Committee to initiate the PhagoDAIR study
02/07/2022 - 17:45
Pherecydes Pharma Announces its Financial Agenda for 2022
01/10/2022 - 17:45
The PhagECOLI project undertaken by Pherecydes Pharma and the CEA receives a €2 million grant from Bpifrance
01/03/2022 - 18:00
2021
Pherecydes Pharma obtains ANSM approval for its PhagoDAIR program, the world’s first study in precision phage therapy
12/22/2021 - 07:00
Pherecydes Pharma continues to strengthen its intellectual property with a first patent granted in China, for its anti-Staphylococcus aureus phages
12/16/2021 - 07:00
Pherecydes - First patent granted in Israel for anti-Staphylococcus aureus phages and update on the development schedule
11/29/2021 - 07:00
Pherecydes Pharma announces the appointment of Dr. Pascal Birman as Medical Director
10/20/2021 - 18:00
Pherecydes Pharma publishes its half-year 2021 financial results and assesses its positive development momentum
10/13/2021 - 07:00
Pherecydes Pharma announces its participation in a number of major scientific conferences and investor events in H2 2021
09/08/2021 - 17:45
Pherecydes Pharma will present its work on the provision of bacteriophages for therapeutic use at the France Bioproduction congress
06/16/2021 - 17:45
The results of a preclinical trial demonstrating the benefits of inhaled Pherecydes Pharma phages in treating ventilation-associated pneumonia have been published in the prestigious British Journal of Pharmacology
06/07/2021 - 18:00
Pherecydes Pharma expands its patent portfolio with a new patent granted in Hong Kong
05/11/2021 - 07:00
A new scientific publication highlights the beneficial effect of Pherecydes Pharma phages in treating a case of prosthetic knee infection
05/06/2021 - 07:00
Pherecydes Pharma obtains €2 million in non-dilutive financing from Bpifrance
04/29/2021 - 18:00
Portzamparc initiates the coverage of Pherecydes Pharma
04/28/2021 - 07:00
Pherecydes Pharma announces its 2020 annual financial results and confirms its 2021 outlook
04/15/2021 - 07:00
A preclinical trial demonstrates the benefits of inhaled Pherecydes Pharma phages in treating ventilation-associated pneumonia
04/08/2021 - 18:00
Pherecydes Pharma strengthens its Management Committee: recruitment of Céline Breda as Director of Industrial Operations
03/31/2021 - 18:00
Pherecydes Pharma Announces its Financial Agenda for 2021
03/22/2021 - 18:00
Pherecydes Pharma’s phage production project (PhagoPROD) featured in the European Commission’s CORDIS magazine
03/15/2021 - 18:00
Strengthening of Pherecydes Pharma’s patent portfolio with two new patents granted in the United States
02/16/2021 - 18:00
Resounding success of Pherecydes Pharma’s IPO on the Euronext Growth® market in Paris
02/02/2021 - 20:27
Pherecydes Pharma brings forward the closing of its IPO to February 1, 2021, given its strong success with investors
01/29/2021 - 08:20
Pherecydes Pharma announces its intention to list on the Euronext Growth® market in Paris
01/05/2021 - 07:30
Financial calendar and upcoming events
November 28, 2023
Investir Day - Paris - Carrousel du Louvre - https://www.investirday.fr/
December 05, 2023
Geneva MidCap Event - Royal Hotel - Participants: Thibaut du Fayet, Eric Soyer https://geneva2023.cfbcom.com/
Past webcasts
HYR 2023 presentation [PDF]
ERYTECH – Webcast of Thursday, February 16, 2023 on the proposed merger between Erytech and Pherecydes [PDF]
ERYTECH – Webconference Tuesday November 22, 2022: Q3 2022 quarterly results [PDF]
ERYTECH – Webconference Tuesday, September 13, 2022: Q2 and H1 2022 results [PDF]
ERYTECH – Webconference on Monday, March 14, 2022: Q4 and full-year results 2021 [PDF]
ERYTECH – Webconference Tuesday November 16, 2021: Q3 2021 quarterly results [PDF]
ERYTECH – Webconference September 21, 2021: H1 2021 results [PDF]
ERYTECH – Webconference May 5, 2021: Quarterly results Q1 2021 [PDF]
ERYTECH – Webconference March 9, 2021: full-year results 2020 [PDF]
PHERECYDES – January 21, 2021: Investor Presentation - IPO [PDF]
ERYTECH – Webconference November 6, 2020: Q3 2020 quarterly results [PDF]
ERYTECH – Webconference September 22, 2020: H1 2020 results [PDF]
ERYTECH – Webconference May 7, 2020: Q1 2020 quarterly results [PDF]
ERYTECH – Webconference March 17, 2020: full-year results 2019 [PDF]
Universal Registration Document
2020
Financial reports
Financial reports
2021
PHERECYDES - 2021 annual financial report (in French)
2020
PHERECYDES - 2020 annual financial report (in French)
2019
ERYTECH – Half-year financial report 2019 [PDF]
2018
ERYTECH – Half-year financial report 2018 [PDF]
2017
ERYTECH – Half-year financial report 2017 [PDF - in French]
2016
ERYTECH – Half-year financial report 2016 [PDF]
2015
ERYTECH – Half-year financial report 2015 [PDF]
ERYTECH – Reference Document 2015 (including Annual financial report 2015) [PDF]
Quarterly Financial Information
2021
Erytech provides financial update for Q3 2021
Erytech provides financial update for Q2 2021
Erytech provides financial update for Q1 2021
2020
Erytech provides financial results for the full year 2020
Erytech provides financial update for Q3 2020
Erytech provides financial update for Q2 2020
Erytech provides financial update for Q1 2020
2019
Erytech provides financial results for the full year 2019
Erytech provides financial update for Q3 2019
Erytech provides financial update for Q2 2019
Erytech provides financial update for Q1 2019
2018
Erytech provides financial update for Q4 2018
Erytech provides financial update for Q3 2018
Erytech provides financial update for Q2 2018
Erytech provides financial update for Q1 2018
2017
Erytech provides financial update for Q4 2017
Erytech provides financial update for Q3 2017
Erytech provides financial update for Q2 2017
Erytech provides financial update for Q1 2017
2016
Erytech provides financial update for Q4 2016
Erytech provides financial update for Q3 2016
Erytech provides financial update for Q2 2016
Erytech provides financial update for Q1 2016
2015
Erytech provides financial update for Q4 2015
Erytech provides financial update for Q3 2015
Erytech provides financial update for Q2 2015
Erytech provides financial update for Q1 2015
2014
Erytech provides financial update for Q2 2014
Erytech provides financial update for Q1 2014
2013
Erytech gives feedback on its first Investor R&D Day and provides a financial and business update for Q4 2013
Erytech provides financial update for Q3 2013
Erytech provides financial update for Q2 2013
Erytech Pharma provides financial update for Q1 2013
Periodical information
Total Numbers of Voting Rights and Shares
2023
Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2023
Monthly information related to total number of voting rights and shares composing the share capital – November 31, 2023
Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2023
Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2023
Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2023
Monthly information related to total number of voting rights and shares composing the share capital – July 31, 2023
Monthly information related to total number of voting rights and shares composing the share capital – June 26, 2023
Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2023
Monthly information related to total number of voting rights and shares composing the share capital – May 17, 2023
Monthly information related to total number of voting rights and shares composing the share capital – May 15, 2023
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2023
Monthly information related to total number of voting rights and shares composing the share capital – March 31, 2023
Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2023
Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2023
2022
Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2022
Monthly information related to total number of voting rights and shares composing the share capital – November 30, 2022
Monthly information related to total number of voting rights and shares composing the share capital – October 30, 2022
Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2022
Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2022
Monthly information related to total number of voting rights and shares composing the share capital – July 31, 2022
Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2022
Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2022
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2022
Monthly information related to total number of voting rights and shares composing the share capital – March 31, 2022
Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2022
Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2022
2021
PHERECYDES - Shares and voting Rights - June 2021
PHERECYDES - Shares and voting Rights - May 2021
PHERECYDES - Shares and voting Rights - April 2021
PHERECYDES - Shares and voting Rights - March 2021
2020
Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2020
Monthly information related to total number of voting rights and shares composing the share capital – november 30, 2020
Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2020
Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2020
Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2020
Monthly information related to total number of voting rights and shares composing the share capital – July 31, 2020
Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2020
Monthly information related to total number of voting rights and shares composing the share capital – May 30, 2020
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2020
Monthly information related to total number of voting rights and shares composing the share capital – March 31, 2020
Monthly information related to total number of voting rights and shares composing the share capital – February 29, 2020
Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2020
2019
Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2019
Monthly information related to total number of voting rights and shares composing the share capital – November 30, 2019
Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2019
Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2019
Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2019
Monthly information related to total number of voting rights and shares composing the share capital – July 31, 2019
Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2019
Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2019
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2019
Monthly information related to total number of voting rights and shares composing the share capital – March 31, 2019
Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2019
Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2019
2018
Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2018
Monthly information related to total number of voting rights and shares composing the share capital – November 30, 2018
Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2018
Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2018
Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2018
Monthly information related to total number of voting rights and shares composing the share capital – July 31, 2018
Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2018
Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2018
Monthly information related to total number of voting rights and shares composing the share capital – April 31, 2018
Monthly information related to total number of voting rights and shares composing the share capital – March 31, 2018
Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2018
Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2018
2017
Information related to total number of voting rights and shares December 2017
2016
Information related to total number of voting rights and shares December 2016
2015
Information related to total number of voting rights and shares December 2015
2014
Information related to total number of voting rights and shares December 2014
2013
Information related to total number of voting rights and shares December 2013
Other documents
2022
ERYTECH - Note warrant transaction consisting of tranches of convertible bonds with warrants attached
2021
ERYTECH - At-the-market program allowing the issuance of ordinary shares in the form of ads
Equity offerings
2021
ERYTECH - Note d'opération décembre 2021 (in French)
ERYTECH - Note d'opération Mai 2021 (in French)
PHERECYDES - Investors Presentation - IPO
2017
ERYTECH - Prospectus IPO NASDAQ (in French)
ERYTECH - Securities note
2015
ERYTECH - Note d'opération (in French)
2014
ERYTECH - Securities note
2013
ERYTECH - Prospectus IPO in French
Dépôts SEC
Shareholders Meetings
2023
Report of the Merger Auditor on the remuneration of the contributions
Exemption document prepared in connection with the merger by absorption of Pherecydes Pharma by Erytech Pharma
Merger Auditor’s report on the value of the contributions
Notice of the proposed merger
Presentation of additional information for the Annual General Meeting 2023
Capital Contributions Auditors report on the value of the contribution
Capital Contributions Auditors report on the remuneration of the contribution
Notice of meeting published within the BALO (French version)
Convening Notice AGM 2023
AGM Board of Director’ report
Request form of documents related to the General Meeting
Postal voting form and proxy form
Additional report of the Board of Directors dated May 15, 2023
Monthly information related to total number of voting rights and shares composing the share capital – May 17 2023
Letter from Gil Beyen, CEO, regarding the proposed merger with Pherecydes Pharma
Voting results by resolution
Statutory auditors' report on the capital increase reserved for members of a company savings plan (french version)
Statutory auditors' report on the capital reduction (french version)
Statutory auditors' report on the authorization to issue stand-alone share warrants without pre-emptive subscription rights (french version)
Statutory auditors' report on the authorization to grant stock options (french version)
Statutory auditors' report on the authorization to grant existing or future free shares (french version)
Statutory auditors' report on the issue of shares and share equivalents with or without pre-emptive subscription rights (french version)
Statutory Auditors’ special report on regulated agreements
Statutory auditors’ report on the consolidated financial statements
Statutory auditors’ report on the financial statements
Press release: ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023
2022
PHERECYDES - Results of the vote per resolution (French only)
12/21/2022
PHERECYDES - Postal voting form
11/30/2022
PHERECYDES - Notice of meeting (French only)
11/30/2022
PHERECYDES - Text of resolutions (French only)
11/30/2022
PHERECYDES - Notice of meeting published in the JAL (French only)
11/30/2022
PHERECYDES - Convening notice GM Dec 15, 2022 (French only)
11/09/2022
ERYTECH - Convening Notice AGM 2022
ERYTECH - Auditor's special report on regulated agreements
ERYTECH - Statutory auditors’ report on the consolidated financial statements
ERYTECH - Statutory auditors’ report on the financial statements
ERYTECH - AGM Board of Director’ report
ERYTECH - Request form of documents related to the General Meeting
ERYTECH - Postal voting form and proxy form
ERYTECH - Special report of the Board of Directors on share subscription and purchase options
ERYTECH - Special report of the Board of Directors with regard to the allocation of bonus shares
ERYTECH - Additional report of the Board of Directors on July 27, 2021 (warrants)
ERYTECH - Additional report of the Board of Directors on June 25, 2021 (registered offering)
ERYTECH - Additional report of the Board of Directors on April 26, 2022 (registered offering)
ERYTECH - French BALO publication
ERYTECH - Information related to total number of voting rights and shares
ERYTECH - Voting results by resolution
ERYTECH - 2021 Universal Document Registration
PHERECYDES - Minutes GM May 19, 2022 (french only)
06/22/2022
PHERECYDES - Deck GM May 19, 2022 (French only)
05/19/2022
PHERECYDES - Statutory auditors' fees (French only)
05/16/2022
PHERECYDES - Proxy Form GM May 19, 2022
05/04/2022
PHERECYDES - Board of directors’ general report GM May 19, 2022 (French only)
05/04/2022
PHERECYDES - Draft resolutions GM May 19, 2022 (French only)
05/04/2022
PHERECYDES - Convening notice GM May 19, 2022 (French only)
05/04/2022
2021
Information regarding the total number of the outstanding shares and voting rights
French BALO publication
Special report of the Board of Directors on share subscription and purchase options
Additional report of the Board of Directors on March 5, 2021 (ATM)
Request form of documents related to the General Meeting
Convening Notice
Special report of the Board of Directors with regard to the allocation of bonus shares
Additional report of the Board of Directors on January 21, 2021 (OCABSA)
Additional report of the Board of Directors on July 28, 2020 (warrants)
Postal voting form and proxy form
Statutory auditors’ report on the consolidated financial statements
Statutory auditors’ report on the financial statements
AGM Board of Director’ report
Auditor's special report
Voting results by resolution
2020
Convening Notice
Auditor's special report
Statutory auditors’ report on the consolidated financial statements
Statutory auditors’ report on the financial statements
Voting rights on May 22, 2020
AGM Board of Director’ report
Request form of documents related to the General Meeting
Postal voting form and proxy form
Voting results by resolution
2019
2019 Convening Notice
Auditors special report
Statutory auditors’ report on the consolidated financial statements
Statutory auditors’ report on the financial statements
Voting rights on May 17, 2019
AGM Board of directors’ report (English)
AGM Board of directors’ report (French)
Request form of documents related to the General Meeting
Postal voting form and proxy form
Voting results by resolution
2018
2018 Convening Notice
Postal voting form and proxy form
Request form of documents related to the General Meeting
Total number of voting rights and shares composing the share capital on May 23, 2018
Form 20 F 2017 - Please consult https://www.sec.gov/Archives/edgar/data/1624422/000119312518128812/d522997d20f.htm
Voting results by resolution
General meeting review
2017
Notice of meeting
Total number of voting rights and shares composing the share capital on May 22, 2017
Reference document 2016 containing the financial report and the management report
Postal voting form and proxy form
Voting results by resolution
General meeting review
2016
Notice of meeting
Convening notice 2016
Request for documents
Total amount of remuneration paid to the highest-paid persons 2016
Postal voting form and proxy form
Number of shares and voting rights on May 20th, 2016
General Shareholders Meeting's auditors' reports
Voting results of the resolutions submitted to the shareholders at the General Meeting
General Meeting Review
2015
Notice of meeting
Convening notice
Nomination at the board of directors
Accounting and financial information (French Standards)
Accounting and financial information (IFRS Standards)
Request for documents (French version only)
Number of shares and voting rights on May 19th, 2015
Postal voting form and proxy form
2014 Financial report containing the reports of the statutory auditors and including informations related to the officers and Directors of boards (p123 et seq.)
Report of the Board of Directors
Text of resolutions
Voting results of the resolutions submitted to the shareholders at the General Meeting
General Meeting Review
Stock quote
Historical price
Analyst coverage
Company
Analysts
Latest analyst note
Portzamparc
Mohamed Kaabouni
TP ICAP Midcap
Claire Deray
Please note that any opinions, estimates or forecasts regarding ERYTECH Pharma performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of ERYTECH Pharma or its management. ERYTECH Pharma does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
Investor alerts
Would you like to subscribe to our alerts to receive all our investor information directly in your mailbox? Please enter your email address in the field below and select the type of information you are interested in.
We respect your privacy and will not share your data with third parties. You can unsubscribe at any time from alerts to which you have subscribed.
For more information on our data protection policy, please consult our privacy policy.
INVESTORS CONTACT
To contact our investor relations team
PHAXIAM
Eric Soyer
CFO, COO and Deputy General Manager
+33(0)4 78 74 44 38
investors@phaxiam.com
Investor relations
NewCap
Mathilde Bohin / Dusan Oresansky
+33(0)1 44 71 94 94
phaxiam@newcap.eu
Media relations
NewCap
Arthur Rouillé
+33(0)1 44 71 94 94
phaxiam@newcap.eu